Understanding GLP-1 signaling: A path to better therapies

About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, ...
Drug Target Review

New precision GLP-1 agonist could reduce side effects in patients

Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.
Seeking Alpha

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of ...

WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral ...
Mirage News

GLP-1 Signaling Unlocks Path to Better Therapies

About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, obesity, or other conditions ...